Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac IPO & Placement Research, China biotech

ESR-REIT/Sabana Merger - Buying Well Below Book

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

<p>ESR-REIT announced an S$100 million private placement and S$75 million preferential offerings for the existing unitholders. In this insight, we will provide our thoughts on the deal and score the deal in our ECM framework. </p>

ESR-REIT announced an S$100 million private placement and S$75 million preferential offerings for the existing unitholders. In this insight, we will provide our thoughts on the deal and score the deal in our ECM framework. 

ESR-REIT Placement: Acquisition and AEI Are DPU Accretive but Debt Payment Dilutes

ESR-LOGOS REIT

ESR-REIT Placement: Acquisition and AEI Are DPU Accretive but Debt Payment Dilutes